Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Phase 2 Study of a Live Attenuated Measles Virus-Vectored Chikungunya Vaccine in a Previously Epidemic Area

Trial Profile

Phase 2 Study of a Live Attenuated Measles Virus-Vectored Chikungunya Vaccine in a Previously Epidemic Area

Active, no longer recruiting
Phase of Trial: Phase II

Latest Information Update: 28 Jun 2018

At a glance

  • Drugs Chikungunya virus vaccine (Primary) ; Measles mumps and rubella virus vaccine
  • Indications Chikungunya virus infections
  • Focus Adverse reactions
  • Sponsors Themis Bioscience
  • Most Recent Events

    • 19 Jun 2018 Status changed from recruiting to active, no longer recruiting.
    • 17 Aug 2017 Status changed from not yet recruiting to recruiting.
    • 01 Aug 2017 Planned initiation date changed from 24 May 2017 to 1 Aug 2017.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top